Research Article

Administration of sildenafil citrate not able to reduced hs-CRP on erectile dysfunction patient at Doctor Soetomo Hospital, Surabaya, Indonesia

I Gusti Ngurah Pramesemara , Rossy Sintya Marthasari, Rezia Octarina, Ahmad Ricardo Syukur Silalahi, Judie Hartono, Tjahjo Djojo Tanojo

I Gusti Ngurah Pramesemara
Andrology Department, Doctor Soetomo General Hospital, Surabaya, Indonesia Biomedicine Department, Medical Faculty of Airlangga University, Surabaya, Indonesia. Email: pramareola14@ymail.com

Rossy Sintya Marthasari
Andrology Department, Doctor Soetomo General Hospital, Surabaya, Indonesia Biomedicine Department, Medical Faculty of Airlangga University, Surabaya, Indonesia

Rezia Octarina
Andrology Department, Doctor Soetomo General Hospital, Surabaya, Indonesia Biomedicine Department, Medical Faculty of Airlangga University, Surabaya, Indonesia

Ahmad Ricardo Syukur Silalahi
Andrology Department, Doctor Soetomo General Hospital, Surabaya, Indonesia Biomedicine Department, Medical Faculty of Airlangga University, Surabaya, Indonesia

Judie Hartono
Andrology Department, Doctor Soetomo General Hospital, Surabaya, Indonesia Biomedicine Department, Medical Faculty of Airlangga University, Surabaya, Indonesia

Tjahjo Djojo Tanojo
Andrology Department, Doctor Soetomo General Hospital, Surabaya, Indonesia Biomedicine Department, Medical Faculty of Airlangga University, Surabaya, Indonesia
Online First: August 01, 2019 | Cite this Article
Pramesemara, I., Marthasari, R., Octarina, R., Silalahi, A., Hartono, J., Tanojo, T. 2019. Administration of sildenafil citrate not able to reduced hs-CRP on erectile dysfunction patient at Doctor Soetomo Hospital, Surabaya, Indonesia. Intisari Sains Medis 10(2). DOI:10.15562/ism.v10i2.410


Background: Phosphodiesterase type-5 (PDE5) inhibitors was the first choice for the oral treatment of erectile dysfunction because of its ability to prevent endothelial dysfunction and restored erectile function properly. However, the inflammatory parameter such as hs-CRP can be used to assess the performance of PDE5 inhibitors as well as clinical questionnaires, IIEF-5, and EHS. So that, this study aims to determine the effect of PDE5 inhibitors administration such as sildenafil citrate 50 mg per day can decrease the value of hs-CRP, as well as increased the IIEF-5 and EHS at Dr. Soetomo General Hospital.

Methods: A true clinical experimental studies used pretest and posttest control group design were carried out among 20 patients during 4 weeks. In the next 2 weeks, the crossover was conducted among respondents for the washout period whereas divided into 2 groups, control (K1 and K2) and treatment (P1 and P2). Data were analyzed using Statistical Package for the Social Sciences (SPSS) version 16.0 software for Windows.

Results: The average age of group K1 and P2 was 51 ± 12.07 years old whereas 48.60 ± 15.40 years old in group P1 and K2. The research was conducted in Andrology Clinic of Doctor Soetomo Hospital in Surabaya during June to November 2017. The research data were not normally distributed, then analyzed by two-tail T-group tests and Wilcoxon test at significance level α=0.05. The results showed that PDE5 inhibitors did not decrease the hs-CRP significantly (p>0.05), but increased EHS (p<0.05) and increased IIEF-5 (p<0.05) significantly.

Conclusion: This study concluded that the administration of sildenafil citrate per day by oral increased the EHS and IIEF-5, but not able to reduced hs-CRP in patients with erectile dysfunction significantly.

References

Teloken PE, Mulhall JP. Impact of phosphodiesterase type 5 inhibitors on endothelial function. Rev Urol. 2008; 10(1):26-30.

Arcaniolo D, Autorino R, Balsamo R, De Sio M. Optimum Use of Second Line Treatment Options for Erectile Dysfunction. Practical Tips in Urology. 2017; 157-177.

Lee JW, Park HJ, Park NC. Serum High-Sensitivity C-Reactive Protein Levels and Response to 5 mg Tadalafil Once Daily in Patients With Erectile Dysfunction and Diabetes. Korean Journal of Urology. Korean J Urol. 2013; 54(12): 858–864

Su JB. Vascular Endothelial Dysfunction and Pharmacological Treatment. World J Cardiol. 2015; 7(11):719-41

Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999; 11(6):319-26.

Pohjantähti-Maaroos H, Palomäki A, Hartikainen J. Erectile dysfunction, physical activity and metabolic syndrome: differences in markers of atherosclerosis. BMC Cardiovasc Disord. 2011; 11:36.

Tamler R, Bar-Chama N. Assessment of endothelial function in the patient with erectiledysfunction: an opportunity for the urologist. Int J Impot Res. 2008; 20(4):370-7.

Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A Multicenter, Randomized, Double-Blind, Crossover Study of Patient Preference for Tadalafil 20 mg or Sildenafil Sitrat 50 mg During Initiation of Treatment for Erectile Dysfunction. Clin Ther. 2003; 25(11):2709-23.

Aversa A, Bruzziches R, Francomano D, Natali M, Gareri P, Spera G. Endothelial dysfunction and erectile dysfunction in the aging man. Int J Urol. 2010; 17(1):38-47.

Park HJ, Moon KH, Lee SW, Lee WK, Kam SC, Lee JH, Park NC. Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. World J Mens Health. 2014; 32(1):18-27.

Sung HH. Sung WL. Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. Korean J Urol. 2012 ;53(6):377-85.

Santi D, Giannetta E, Isidori AM, Vitale C, Aversa A, Simoni M. Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2diabetes mellitus: a meta-analysis. Eur J Endocrinol. 2015 ;172(3):R103-14.

Satriyasa BK. Tadalafil as new oral treatment for erectile dysfunction: a review. Bali Med J. 2017; 6(1):56-59


No Supplementary Material available for this article.
Article Views      : 23
PDF Downloads : 9